Sodium–glucose co‐transporter‐2 inhibitor cardiovascular outcome trials and generalizability to English primary care-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Sodium–glucose co‐transporter‐2 inhibitor cardiovascular outcome trials and generalizability to English primary care

Published:2020-03-28 Issue:9 Volume:37 Page:1499-1508
ISSN:0742-3071
Container-title:Diabetic Medicine
language:en
Short-container-title:Diabet. Med.

Author:

Hinton W.¹²,Feher M.¹,Munro N.²,Joy M.¹²,Lusignan S.¹²³

Affiliation:

1. Nuffield Department of Primary Care Health Sciences University of Oxford Oxford UK

2. Department of Clinical and Experimental Medicine University of Surrey Guildford UK

3. Royal College of General Practitioners Research and Surveillance Centre London UK

Funder

AstraZeneca

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dme.14290

Reference30 articles.

1. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

2. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

3. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

4. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Generalizability and treatment with sodium-glucose co-trasporter-2 inhibitors (SGLT2i) among patients with type 2 diabetes: an assessment using an Italian primary care database;Acta Diabetologica;2024-08-29

2. Sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes: Are clinical trial benefits for heart failure reflected in real‐world clinical practice? A systematic review and meta‐analysis of observational studies;Diabetes, Obesity and Metabolism;2022-11-02

3. Registry-based randomised clinical trials: a remedy for evidence-based diabetes care?;Diabetologia;2022-07-29

4. The potential role of EHR data in optimizing eligibility criteria definition for cardiovascular outcome trials;International Journal of Medical Informatics;2021-12

5. External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease;Cardiovascular Diabetology;2021-09-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3